The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii

多重耐药病原体鲍曼不动杆菌的细胞包膜

基本信息

  • 批准号:
    10328269
  • 负责人:
  • 金额:
    $ 53.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-25 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

The bacterial cell envelope is a remarkable and complex structure that guards bacteria from their surrounding environment. A defining feature of Gram-negative bacteria is the presence of an outer membrane (OM) that encapsulates the peptidoglycan layer of these organisms. While the inner membrane (IM) is composed of glycerophospholipids (GPLs), the OM is a bilayer with extreme lipid asymmetry with GPL confined to the inner leaflet and lipopolysaccharide (LPS) localized to the outer leaflet. This unique membrane organization affords Gram-negative bacteria protection from large polar molecules, as well as lipophilic compounds, serving as an essential innate barrier to a variety of antibiotics and toxic compounds. Remarkably, the high-priority Gram-negative pathogen Acinetobacter baumannii can completely inactivate LPS biosynthesis as an alternative mechanism of resistance to the “last-resort” antibiotics called polymyxins. The primary objective of this application is to investigate the mechanisms required for maintenance of the cell envelope of A. baumannii, regardless of LPS status. While the benefit of an asymmetric OM relative to a GPL bilayer is apparent due to the impermeable barrier it provides, the lack of LPS essentiality in A. baumannii can be used a tool to explore novel mechanisms of OM stability in both the presence or absence of LPS. In Aim 1, we will investigate changes to the bacterium during its transition from an LPS-deficient to a LPS-positive cell, including how GPL transport influences LPS structure. For Aim 2 our focus will be the identification of genes that support LPS-deficiency, including the role of lipoproteins and how they are transported to the cell surface regardless of LPS status. Finally, in Aim 3, we will characterize novel gene products necessary for OM stability in LPS-positive A. baumannii uncovered by a genetic and chemical synthetic lethality screen. Given the current literature, the application is built on a strong scientific premise addressing major gaps in our understanding of the A. baumannii cell envelope and other Gram-negative pathogens. Furthermore, the Aims focus on highly conserved pathways that impact membrane biogenesis, bacterial pathogenesis, and antimicrobial development.
细菌的细胞包膜是一个显著的和复杂的结构,保护细菌免受周围环境的影响。革兰氏阴性菌的一个决定性特征是存在外膜(OM),该外膜包裹着这些生物的肽聚糖层。虽然内膜(IM)由甘油磷脂(GPL)组成,但内膜是一个脂质极端不对称的双层,GPL局限于内小叶,脂多糖(LPS)局限于外小叶。这种独特的膜组织为革兰氏阴性细菌提供了保护,使其免受大分子极性以及亲脂性化合物的侵害,成为抵抗各种抗生素和有毒化合物的基本天然屏障。值得注意的是,高优先级的革兰氏阴性病原体鲍曼不动杆菌可以完全灭活LPS生物合成,作为对“最后手段”抗生素多粘菌素耐药的另一种机制。本应用程序的主要目的是研究鲍曼不动杆菌在不考虑LPS状态的情况下维持细胞包膜所需的机制。虽然不对称OM相对于GPL双分子层的好处是显而易见的,因为它提供了不可渗透的屏障,但鲍曼不动杆菌缺乏LPS的必要性可以用作探索存在或不存在LPS的OM稳定性新机制的工具。在Aim 1中,我们将研究细菌从LPS缺陷细胞向LPS阳性细胞转变过程中的变化,包括GPL转运如何影响LPS结构。对于Aim 2,我们的重点将是鉴定支持脂多糖缺乏的基因,包括脂蛋白的作用以及无论脂多糖状态如何,它们如何运输到细胞表面。最后,在Aim 3中,我们将描述通过遗传和化学合成致死筛选发现的lps阳性鲍曼不动杆菌OM稳定性所需的新基因产物。鉴于目前的文献,该应用程序建立在强有力的科学前提上,解决了我们对鲍曼芽胞杆菌包膜和其他革兰氏阴性病原体理解的主要差距。此外,Aims重点关注影响膜生物发生,细菌发病机制和抗菌药物发展的高度保守途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Stephen Trent其他文献

Michael Stephen Trent的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Stephen Trent', 18)}}的其他基金

The role of cardiolipin in the biogenesis of the Gram-negative bacterial cell envelope
心磷脂在革兰氏阴性细菌细胞包膜生物发生中的作用
  • 批准号:
    10731444
  • 财政年份:
    2023
  • 资助金额:
    $ 53.93万
  • 项目类别:
Synthesis and transport of outer membrane components across the Gram-negative cell envelope
外膜成分的合成和跨革兰氏阴性细胞包膜的运输
  • 批准号:
    10680968
  • 财政年份:
    2023
  • 资助金额:
    $ 53.93万
  • 项目类别:
2022 Bacterial Cell Surfaces GRC/GRS
2022 细菌细胞表面GRC/GRS
  • 批准号:
    10374358
  • 财政年份:
    2022
  • 资助金额:
    $ 53.93万
  • 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
  • 批准号:
    10113527
  • 财政年份:
    2020
  • 资助金额:
    $ 53.93万
  • 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
  • 批准号:
    10542396
  • 财政年份:
    2020
  • 资助金额:
    $ 53.93万
  • 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
  • 批准号:
    10159193
  • 财政年份:
    2018
  • 资助金额:
    $ 53.93万
  • 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
  • 批准号:
    10403653
  • 财政年份:
    2018
  • 资助金额:
    $ 53.93万
  • 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
  • 批准号:
    9917747
  • 财政年份:
    2018
  • 资助金额:
    $ 53.93万
  • 项目类别:
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
新型疫苗平台的开发:表面抗原/佐剂疫苗工程(SAAVE)
  • 批准号:
    9899172
  • 财政年份:
    2017
  • 资助金额:
    $ 53.93万
  • 项目类别:
Rethinking the barrier: How a Gram-negative bacterium alters its surface to become multidrug resistant
重新思考屏障:革兰氏阴性细菌如何改变其表面以产生多重耐药性
  • 批准号:
    9102680
  • 财政年份:
    2015
  • 资助金额:
    $ 53.93万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.93万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了